دورية أكاديمية
Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network
| العنوان: | Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network |
|---|---|
| المؤلفون: | Rose, Angela M C, Pozo Sanchez, Francisco, Martínez-Baz, Iván, Mazagatos, Clara, Bossuyt, Nathalie, Cauchi, John Paul, Petrović, Goranka, Loghin, Isabela I, Vaikutyte, Roberta, Buda, Silke, Machado, Ausenda, Duffy, Róisín, Oroszi, Beatrix, Howard, Jennifer, Echeverria, Aitziber, Andreu, Cristina, Barbezange, Cyril, Džiugytė, Aušra, Nonković, Diana, Popescu, Corneliu-Petru, Majauskaite, Fausta, Tolksdorf, Kristin, Gomez, Verónica, Domegan, Lisa, Horváth, Judit Krisztina, Castilla, Jesús, García, Miriam, Demuyser, Thomas, Borg, Maria-Louise, Tabain, Irena, Lazar, Mihaela, Kubiliute, Ieva, Dürrwald, Ralf, Guiomar, Raquel, O'Donnell, Joan, Kristóf, Katalin, Nicolay, Nathalie, Bacci, Sabrina, Kissling, Esther, EBIS SARI VE network team |
| المساهمون: | National Research, Development and Innovation Office (Hungria) |
| بيانات النشر: | Wiley |
| سنة النشر: | 2024 |
| المجموعة: | REPISALUD (REPositorio Institucional en SALUD del Instituto de Salud Carlos III - ISCIII) |
| مصطلحات موضوعية: | Influenza, Human, Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Pneumonia, Adult, Humans, Seasons, H3N2 Subtype, Case-Control Studies, Vaccine Efficacy, Europe, Hospitalization, Hospitals, Vaccination |
| الوصف: | We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% (95% CI: -4-39) against A(H3N2) and 56% (95% CI: 22-75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed. ; The Hungarian study team works as part of the National Labora-tory for Health Security Hungary (RRF-2.3.1-21-2022-00006) supported by the National Research, Development and Innovation Office (NKFIH). ; Sí |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1750-2659 |
| العلاقة: | https://doi.org/10.1111/irv.13255Test; Influenza Other Respir Viruses. 2024 Feb;18(2):e13255.; http://hdl.handle.net/20.500.12105/19060Test; Influenza and other respiratory viruses |
| DOI: | 10.1111/irv.13255 |
| الإتاحة: | https://doi.org/20.500.12105/19060Test https://doi.org/10.1111/irv.13255Test https://hdl.handle.net/20.500.12105/19060Test |
| حقوق: | http://creativecommons.org/licenses/by/4.0Test/ ; Atribución 4.0 Internacional ; open access |
| رقم الانضمام: | edsbas.2E7527E5 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 17502659 |
|---|---|
| DOI: | 10.1111/irv.13255 |